PL4164651T3 - 5-amino-2,3-dihydro-1,4-ftalazinedion do stosowania w leczeniu zakażeń koronawirusowych - Google Patents
5-amino-2,3-dihydro-1,4-ftalazinedion do stosowania w leczeniu zakażeń koronawirusowychInfo
- Publication number
- PL4164651T3 PL4164651T3 PL21732191.8T PL21732191T PL4164651T3 PL 4164651 T3 PL4164651 T3 PL 4164651T3 PL 21732191 T PL21732191 T PL 21732191T PL 4164651 T3 PL4164651 T3 PL 4164651T3
- Authority
- PL
- Poland
- Prior art keywords
- phthalazinedione
- dihydro
- amino
- treatment
- coronaviral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20000212 | 2020-06-10 | ||
| EP20000366.3A EP3981405A1 (en) | 2020-10-08 | 2020-10-08 | Compound for the treatment of coronaviral infections |
| PCT/EP2021/000071 WO2021249667A1 (en) | 2020-06-10 | 2021-06-09 | Compound for the treatment of coronaviral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4164651T3 true PL4164651T3 (pl) | 2026-04-27 |
Family
ID=76444360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21732191.8T PL4164651T3 (pl) | 2020-06-10 | 2021-06-09 | 5-amino-2,3-dihydro-1,4-ftalazinedion do stosowania w leczeniu zakażeń koronawirusowych |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230218614A1 (pl) |
| EP (1) | EP4164651B1 (pl) |
| JP (1) | JP7798858B2 (pl) |
| KR (1) | KR20230027150A (pl) |
| CN (1) | CN116075306B (pl) |
| AU (1) | AU2021288757B2 (pl) |
| BR (1) | BR112022025134A2 (pl) |
| CA (1) | CA3182022A1 (pl) |
| ES (1) | ES3057264T3 (pl) |
| HR (1) | HRP20251678T1 (pl) |
| IL (1) | IL298899A (pl) |
| MX (1) | MX2022015601A (pl) |
| NZ (1) | NZ795921A (pl) |
| PH (1) | PH12022553235A1 (pl) |
| PL (1) | PL4164651T3 (pl) |
| WO (1) | WO2021249667A1 (pl) |
| ZA (1) | ZA202300259B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981405A1 (en) * | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
| US20240075029A1 (en) * | 2020-12-02 | 2024-03-07 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
| EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
| EP4460309B1 (en) * | 2022-01-07 | 2026-08-19 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies |
| EP4209219A1 (en) * | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| EP4483879A1 (en) | 2023-06-29 | 2025-01-01 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders |
| EP4494632A1 (en) * | 2023-07-19 | 2025-01-22 | Consejo Superior de Investigaciones Científicas (CSIC) | Lipophilic-based composition |
| EP4784132A1 (en) | 2023-09-26 | 2026-08-05 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9011833D0 (en) * | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
| US7326690B2 (en) * | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| US6953799B1 (en) | 2002-10-30 | 2005-10-11 | Bach Pharma, Inc. | Modulation of cell fates and activities by diketo phthalazines |
| ITMI20052036A1 (it) | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato |
| PL231885B1 (pl) | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| PT2542535E (pt) | 2010-03-01 | 2014-08-25 | Metriopharm Ag | Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas |
| EP2688565A1 (en) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| JP2017537958A (ja) | 2014-12-18 | 2017-12-21 | メトリオファーム アーゲー | ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法 |
| WO2017140422A1 (en) * | 2016-02-16 | 2017-08-24 | Metriopharm Ag | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
| CN109563052A (zh) * | 2016-02-16 | 2019-04-02 | 麦翠奥制药公司 | 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体 |
| EP3248602A1 (en) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae |
| DK3534904T3 (da) | 2016-11-07 | 2022-04-11 | Metriopharm Ag | Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose |
| EP3858358A1 (en) * | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
| PL4125802T3 (pl) * | 2020-03-25 | 2026-03-23 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc |
| RU2747467C1 (ru) * | 2020-07-17 | 2021-05-05 | Муса Тажудинович Абидов | Способ защиты от коронавирусной инфекции |
-
2021
- 2021-06-09 AU AU2021288757A patent/AU2021288757B2/en active Active
- 2021-06-09 CN CN202180056484.XA patent/CN116075306B/zh active Active
- 2021-06-09 PH PH1/2022/553235A patent/PH12022553235A1/en unknown
- 2021-06-09 JP JP2023506134A patent/JP7798858B2/ja active Active
- 2021-06-09 BR BR112022025134A patent/BR112022025134A2/pt unknown
- 2021-06-09 MX MX2022015601A patent/MX2022015601A/es unknown
- 2021-06-09 NZ NZ795921A patent/NZ795921A/en unknown
- 2021-06-09 KR KR1020237000847A patent/KR20230027150A/ko active Pending
- 2021-06-09 IL IL298899A patent/IL298899A/en unknown
- 2021-06-09 WO PCT/EP2021/000071 patent/WO2021249667A1/en not_active Ceased
- 2021-06-09 EP EP21732191.8A patent/EP4164651B1/en active Active
- 2021-06-09 US US18/001,034 patent/US20230218614A1/en active Pending
- 2021-06-09 HR HRP20251678TT patent/HRP20251678T1/hr unknown
- 2021-06-09 PL PL21732191.8T patent/PL4164651T3/pl unknown
- 2021-06-09 CA CA3182022A patent/CA3182022A1/en active Pending
- 2021-06-09 ES ES21732191T patent/ES3057264T3/es active Active
-
2023
- 2023-01-05 ZA ZA2023/00259A patent/ZA202300259B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4164651A1 (en) | 2023-04-19 |
| NZ795921A (en) | 2026-03-27 |
| ES3057264T3 (en) | 2026-02-27 |
| KR20230027150A (ko) | 2023-02-27 |
| MX2022015601A (es) | 2023-01-30 |
| AU2021288757B2 (en) | 2026-01-08 |
| BR112022025134A2 (pt) | 2022-12-27 |
| IL298899A (en) | 2023-02-01 |
| JP2023529022A (ja) | 2023-07-06 |
| WO2021249667A1 (en) | 2021-12-16 |
| AU2021288757A1 (en) | 2023-02-02 |
| CA3182022A1 (en) | 2021-12-16 |
| ZA202300259B (en) | 2024-05-30 |
| US20230218614A1 (en) | 2023-07-13 |
| EP4164651B1 (en) | 2025-10-15 |
| CN116075306B (zh) | 2024-12-27 |
| PH12022553235A1 (en) | 2024-02-12 |
| JP7798858B2 (ja) | 2026-01-14 |
| HRP20251678T1 (hr) | 2026-02-13 |
| EP4164651C0 (en) | 2025-10-15 |
| CN116075306A (zh) | 2023-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251678T1 (hr) | 5-amino-2,3-dihidro-1,4-ftalazindion za uporabu u liječenju koronavirusnih infekcija | |
| EP3980400A4 (en) | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| WO2015138716A3 (en) | Anti-infective and osteogenic compositions and methods of use | |
| IL250858A0 (en) | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | |
| WO2006013441A3 (en) | Use of probiotic bacteria for the preparation of topical compositions for skin protection | |
| WO2004069156A3 (en) | Inactivated probiotic bacteria and methods of use thereof | |
| AU2020217620B2 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| PH12019500083A1 (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
| EP4125802C0 (en) | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZIN IONES FOR THE TREATMENT OF ACUTE LUNG INJURIES | |
| HUE071698T2 (hu) | Glükokortikoid-csökkentõ szer | |
| EP4620526A3 (en) | Pharmaceutical combination comprising ponesimod and its use in the treatment of multiple sclerosis | |
| DK3292867T3 (da) | Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion | |
| EP3583945A4 (en) | PULMONARY FIBROSIS TREATMENT AGENT, PTPRR EXPRESSION PROMOTIONER, AND PULMONARY FIBROSIS TREATMENT KIT | |
| IL288861A (en) | A drug and its use for the treatment of bacterial infections associated with biofilm | |
| EP3968872A4 (en) | SURGICAL TOOLS AND METHODS OF USE | |
| EA200400197A1 (ru) | Способы получения поливалентных бактериофагов для лечения бактериальных инфекций | |
| ZA202211706B (en) | Medicine/agent for the treatment of coronavirus, retroviral infections and hepatitis c | |
| EP4282382A4 (en) | IMPLANT DELIVERY HANDLE, IMPLANT SYSTEM, IMPLANT DELIVERY SYSTEM AND METHOD OF USE THEREOF | |
| EP4062844A4 (en) | Endoscopic cap, endoscopic treatment tool, and endoscope system | |
| SG11202102791SA (en) | Indane derivatives for use in the treatment of bacterial infection | |
| PL4326068T3 (pl) | Środek odkażający i jego zastosowanie | |
| GEAP202015119A (en) | Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition | |
| PL376756A1 (pl) | Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych | |
| EP3753584A4 (en) | STERILIZER AND ITS STERILIZATION PROCESS |